請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78429完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 賈景山(Jean-San Chia) | |
| dc.contributor.author | Chien-Wei Lai | en |
| dc.contributor.author | 賴建瑋 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:56:33Z | - |
| dc.date.available | 2026-01-27 | |
| dc.date.copyright | 2021-02-25 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-01-27 | |
| dc.identifier.citation | 1 Bagan, J., Sarrion, G. Jimenez, Y. Oral cancer: clinical features. Oral Oncol 46, 414-417, doi:10.1016/j.oraloncology.2010.03.009 (2010). 2 Coelho, B. A. et al. Keratins 17 and 19 expression as prognostic markers in oral squamous cell carcinoma. Genet Mol Res 14, 15123-15132, doi:10.4238/2015.November.24.21 (2015). 3 Zhong, L. P., Chen, W. T., Zhang, C. P. Zhang, Z. Y. Increased CK19 expression correlated with pathologic differentiation grade and prognosis in oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104, 377-384, doi:10.1016/j.tripleo.2006.07.019 (2007). 4 Brierley, J. D., Gospodarowicz, M. K. Wittekind, C. TNM classification of malignant tumours. (John Wiley Sons, 2017). 5 Bryne, M. Is the invasive front of an oral carcinoma the most important area for prognostication? Oral Dis 4, 70-77, doi:10.1111/j.1601-0825.1998.tb00260.x (1998). 6 Silveira, E. J. et al. Correlation of clinical, histological, and cytokeratin profiles of squamous cell carcinoma of the oral tongue with prognosis. Int J Surg Pathol 15, 376-383, doi:10.1177/1066896907304992 (2007). 7 Herrmann, H., Bar, H., Kreplak, L., Strelkov, S. V. Aebi, U. Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol 8, 562-573, doi:10.1038/nrm2197 (2007). 8 Schweizer, J. et al. New consensus nomenclature for mammalian keratins. J Cell Biol 174, 169-174, doi:10.1083/jcb.200603161 (2006). 9 Coulombe, P. A. Omary, M. B. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 14, 110-122, doi:10.1016/s0955-0674(01)00301-5 (2002). 10 Fuchs, E. Weber, K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63, 345-382, doi:10.1146/annurev.bi.63.070194.002021 (1994). 11 Fuchs, E. Cleveland, D. W. A structural scaffolding of intermediate filaments in health and disease. Science 279, 514-519, doi:10.1126/science.279.5350.514 (1998). 12 Gu, L. H. Coulombe, P. A. Keratin function in skin epithelia: a broadening palette with surprising shades. Curr Opin Cell Biol 19, 13-23, doi:10.1016/j.ceb.2006.12.007 (2007). 13 Coulombe, P. A., Tong, X., Mazzalupo, S., Wang, Z. Wong, P. Great promises yet to be fulfilled: defining keratin intermediate filament function in vivo. Eur J Cell Biol 83, 735-746, doi:10.1078/0171-9335-00443 (2004). 14 Magin, T. M., Vijayaraj, P. Leube, R. E. Structural and regulatory functions of keratins. Exp Cell Res 313, 2021-2032, doi:10.1016/j.yexcr.2007.03.005 (2007). 15 Paramio, J. M. Jorcano, J. L. Beyond structure: do intermediate filaments modulate cell signalling? Bioessays 24, 836-844, doi:10.1002/bies.10140 (2002). 16 Omary, M. B., Ku, N. O., Strnad, P. Hanada, S. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 119, 1794-1805, doi:10.1172/JCI37762 (2009). 17 Owens, D. W. Lane, E. B. The quest for the function of simple epithelial keratins. Bioessays 25, 748-758, doi:10.1002/bies.10316 (2003). 18 Kim, S., Wong, P. Coulombe, P. A. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 441, 362-365, doi:10.1038/nature04659 (2006). 19 Oshima, R. G. Apoptosis and keratin intermediate filaments. Cell Death Differ 9, 486-492, doi:10.1038/sj.cdd.4400988 (2002). 20 Bordeleau, F., Myrand Lapierre, M. E., Sheng, Y. Marceau, N. Keratin 8/18 regulation of cell stiffness-extracellular matrix interplay through modulation of Rho-mediated actin cytoskeleton dynamics. PLoS One 7, e38780, doi:10.1371/journal.pone.0038780 (2012). 21 Salas, P. J., Forteza, R. Mashukova, A. Multiple roles for keratin intermediate filaments in the regulation of epithelial barrier function and apico-basal polarity. Tissue Barriers 4, e1178368, doi:10.1080/21688370.2016.1178368 (2016). 22 Pallari, H. M. Eriksson, J. E. Intermediate filaments as signaling platforms. Sci STKE 2006, pe53, doi:10.1126/stke.3662006pe53 (2006). 23 Karantza, V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 30, 127-138, doi:10.1038/onc.2010.456 (2011). 24 Paramio, J. M. et al. Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol 19, 3086-3094, doi:10.1128/mcb.19.4.3086 (1999). 25 Presland, R. B. Jurevic, R. J. Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. J Dent Educ 66, 564-574 (2002). 26 van der Velden, L. A., Manni, J. J., Ramaekers, F. C. Kuijpers, W. Expression of intermediate filament proteins in benign lesions of the oral mucosa. Eur Arch Otorhinolaryngol 256, 514-519, doi:10.1007/s004050050202 (1999). 27 Morgan, P. R., Shirlaw, P. J., Johnson, N. W., Leigh, I. M. Lane, E. B. Potential applications of anti-keratin antibodies in oral diagnosis. J Oral Pathol 16, 212-222, doi:10.1111/j.1600-0714.1987.tb02068.x (1987). 28 Shabana, A. H., Ouhayoun, J. P., Sawaf, M. H. Forest, N. A comparative biochemical and immunological analysis of cytokeratin patterns in the oral epithelium of the miniature pig and man. Arch Oral Biol 34, 249-259, doi:10.1016/0003-9969(89)90065-4 (1989). 29 Ogden, G. R., McQueen, S., Chisholm, D. M. Lane, E. B. Keratin profiles of normal and malignant oral mucosa using exfoliative cytology. J Clin Pathol 46, 352-356, doi:10.1136/jcp.46.4.352 (1993). 30 Park, S. Y., Kim, H. S., Hong, E. K. Kim, W. H. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33, 1078-1085, doi:10.1053/hupa.2002.129422 (2002). 31 Kim, M. A., Lee, H. S., Yang, H. K. Kim, W. H. Cytokeratin expression profile in gastric carcinomas. Hum Pathol 35, 576-581, doi:10.1016/j.humpath.2003.12.007 (2004). 32 Fillies, T. et al. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer 6, 10, doi:10.1186/1471-2407-6-10 (2006). 33 Xu, X. C. et al. Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis. Cancer Epidemiol Biomarkers Prev 4, 871-876 (1995). 34 Chu, P. G. Weiss, L. M. Keratin expression in human tissues and neoplasms. Histopathology 40, 403-439, doi:10.1046/j.1365-2559.2002.01387.x (2002). 35 Ikeda, K., Tate, G., Suzuki, T. Mitsuya, T. Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. Gynecol Oncol 108, 598-602, doi:10.1016/j.ygyno.2007.11.042 (2008). 36 Hendrix, M. J., Seftor, E. A., Chu, Y. W., Trevor, K. T. Seftor, R. E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15, 507-525, doi:10.1007/BF00054016 (1996). 37 Kurokawa, I. et al. Keratin profiles may differ between intraepidermal and intradermal invasive eccrine porocarcinoma. Oncol Rep 16, 473-477 (2006). 38 Moll, R., Franke, W. W., Schiller, D. L., Geiger, B. Krepler, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31, 11-24, doi:10.1016/0092-8674(82)90400-7 (1982). 39 Su, L., Morgan, P. R. Lane, E. B. Protein and mRNA expression of simple epithelial keratins in normal, dysplastic, and malignant oral epithelia. Am J Pathol 145, 1349-1357 (1994). 40 Oshima, R. G., Baribault, H. Caulin, C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev 15, 445-471, doi:10.1007/BF00054012 (1996). 41 Debus, E., Moll, R., Franke, W. W., Weber, K. Osborn, M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 114, 121-130 (1984). 42 Schaafsma, H. E. et al. Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol 136, 329-343 (1990). 43 Trask, D. K. et al. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci U S A 87, 2319-2323, doi:10.1073/pnas.87.6.2319 (1990). 44 Schussler, M. H., Skoudy, A., Ramaekers, F. Real, F. X. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol 140, 559-568 (1992). 45 Woelfle, U., Sauter, G., Santjer, S., Brakenhoff, R. Pantel, K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 10, 2670-2674, doi:10.1158/1078-0432.ccr-03-0114 (2004). 46 Lai, Y. C., Cheng, C. C., Lai, Y. S. Liu, Y. H. Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review. Cancer Genomics Proteomics 14, 219-223, doi:10.21873/cgp.20033 (2017). 47 Pankov, R., Simcha, I., Zoller, M., Oshima, R. G. Ben-Ze'ev, A. Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. J Cell Sci 110 ( Pt 8), 965-974 (1997). 48 Yin, B. et al. Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer. Int J Oncol 48, 1730-1736, doi:10.3892/ijo.2016.3396 (2016). 49 Santamaria, L., Ingelmo, I., Sinues, B., Martinez, L. Teba, F. Quantification of the heterogeneity of cytokeratin 18 immunoexpression in prostate adenocarcinoma and normal prostate: Global and local features. Histol Histopathol 33, 1099-1110, doi:10.14670/HH-18-009 (2018). 50 Gires, O., Mack, B., Rauch, J. Matthias, C. CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. Biochem Biophys Res Commun 343, 252-259, doi:10.1016/j.bbrc.2006.02.139 (2006). 51 Makino, T. et al. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer 101, 1298-1306, doi:10.1038/sj.bjc.6605313 (2009). 52 Southgate, J., Harnden, P. Trejdosiewicz, L. K. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 14, 657-664, doi:10.14670/HH-14.657 (1999). 53 Chu, Y. W. et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17, 353-360, doi:10.1165/ajrcmb.17.3.2837 (1997). 54 Hendrix, M. J. et al. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 84, 165-174, doi:10.1093/jnci/84.3.165 (1992). 55 Raul, U. et al. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. Int J Cancer 111, 662-668, doi:10.1002/ijc.20349 (2004). 56 Alam, H., Kundu, S. T., Dalal, S. N. Vaidya, M. M. Loss of keratins 8 and 18 leads to alterations in alpha6beta4-integrin-mediated signalling and decreased neoplastic progression in an oral-tumour-derived cell line. J Cell Sci 124, 2096-2106, doi:10.1242/jcs.073585 (2011). 57 Safadi, R. A. et al. Clinical and histopathologic prognostic implications of the expression of cytokeratins 8, 10, 13, 14, 16, 18 and 19 in oral and oropharyngeal squamous cell carcinoma. Arch Oral Biol 99, 1-8, doi:10.1016/j.archoralbio.2018.12.007 (2019). 58 Kulesh, D. A. Oshima, R. G. Cloning of the human keratin 18 gene and its expression in nonepithelial mouse cells. Mol Cell Biol 8, 1540-1550, doi:10.1128/mcb.8.4.1540 (1988). 59 Kumemura, H. et al. Mutation in keratin 18 induces mitochondrial fragmentation in liver-derived epithelial cells. Biochem Biophys Res Commun 367, 33-40, doi:10.1016/j.bbrc.2007.12.116 (2008). 60 Caulin, C., Ware, C. F., Magin, T. M. Oshima, R. G. Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 149, 17-22, doi:10.1083/jcb.149.1.17 (2000). 61 Gilbert, S., Loranger, A., Daigle, N. Marceau, N. Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 154, 763-773, doi:10.1083/jcb.200102130 (2001). 62 Ku, N. O., Michie, S., Resurreccion, E. Z., Broome, R. L. Omary, M. B. Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci U S A 99, 4373-4378, doi:10.1073/pnas.072624299 (2002). 63 Galarneau, L., Loranger, A., Gilbert, S. Marceau, N. Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res 313, 179-194, doi:10.1016/j.yexcr.2006.10.007 (2007). 64 Fillies, T. et al. Cytokeratin alteration in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep 18, 639-643 (2007). 65 Nanda, K. D., Ranganathan, K., Devi, U. Joshua, E. Increased expression of CK8 and CK18 in leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma: an immunohistochemistry study. Oral Surg Oral Med Oral Pathol Oral Radiol 113, 245-253, doi:10.1016/j.tripleo.2011.05.034 (2012). 66 Frohwitter, G. et al. Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncol Lett 12, 107-113, doi:10.3892/ol.2016.4588 (2016). 67 Balm, A. J., Hageman, P. C., van Doornewaard, M. H., Groeneveld, E. M. Ivanyi, D. Cytokeratin 18 expression in squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 253, 227-233, doi:10.1007/BF00171132 (1996). 68 Yamashiro, Y. et al. Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma. Biochem Biophys Res Commun 399, 365-372, doi:10.1016/j.bbrc.2010.07.077 (2010). 69 Vaidya, M. M., Borges, A. M., Pradhan, S. A. Bhisey, A. N. Cytokeratin expression in squamous cell carcinomas of the tongue and alveolar mucosa. Eur J Cancer B Oral Oncol 32B, 333-336, doi:10.1016/0964-1955(96)00012-7 (1996). 70 Huang, S. et al. [Detection of cytokeratin18 and cytokeratin19 gene expression in blood and tumor tissue of nasopharyngeal carcinoma patients by RT-PCR]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 29, 111-113, 116 (2015). 71 Zhang, B. et al. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer. J Cancer Res Clin Oncol 142, 2479-2487, doi:10.1007/s00432-016-2253-x (2016). 72 Wang, P. B., Chen, Y., Ding, G. R., Du, H. W. Fan, H. Y. Keratin 18 induces proliferation, migration, and invasion in gastric cancer via the MAPK signalling pathway. Clin Exp Pharmacol Physiol, doi:10.1111/1440-1681.13401 (2020). 73 Zhang, J., Hu, S. Li, Y. KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer. Biosci Rep 39, doi:10.1042/BSR20190884 (2019). 74 Akiba, J. et al. The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type. J Clin Pathol 69, 846-851, doi:10.1136/jclinpath-2015-203491 (2016). 75 Messai, Y. et al. Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol 36, 1145-1154, doi:10.3892/ijo_00000597 (2010). 76 Kolostova, K. et al. Molecular characterization of circulating tumor cells in ovarian cancer. Am J Cancer Res 6, 973-980 (2016). 77 Wild, P. J. et al. Artificial intelligence and bladder cancer arrays. Verh Dtsch Ges Pathol 91, 308-319 (2007). 78 Shi, R. et al. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer. Oncol Rep 41, 3015-3026, doi:10.3892/or.2019.7069 (2019). 79 Doebar, S. C. et al. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Am J Pathol 187, 1648-1655, doi:10.1016/j.ajpath.2017.03.012 (2017). 80 Das, D. K., Chakraborty, C., Sawaimoon, S., Maiti, A. K. Chatterjee, S. Automated identification of keratinization and keratin pearl area from in situ oral histological images. Tissue Cell 47, 349-358, doi:10.1016/j.tice.2015.04.009 (2015). 81 Johansson, B., Eriksson, A. Thornell, L. E. Intermediate filament proteins in developing human arteries. Anat Embryol (Berl) 199, 225-231, doi:10.1007/s004290050223 (1999). 82 Moll, R., Divo, M. Langbein, L. The human keratins: biology and pathology. Histochem Cell Biol 129, 705-733, doi:10.1007/s00418-008-0435-6 (2008). 83 Vaidya, M. M. et al. Cytokeratin expression in human fetal tongue and buccal mucosa. J Biosci 25, 235-242, doi:10.1007/BF02703930 (2000). 84 Oyama, K. et al. Serum cytokeratin 18 as a biomarker for gastric cancer. Clin Exp Med 13, 289-295, doi:10.1007/s10238-012-0202-9 (2013). 85 Peduk, S. et al. The Role of Serum CK18, TIMP1, and MMP-9 Levels in Predicting R0 Resection in Patients with Gastric Cancer. Dis Markers 2018, 5604702, doi:10.1155/2018/5604702 (2018). 86 Kilic-Baygutalp, N. et al. Evaluation of serum HGF and CK18 levels in patients with esophageal cancer. Genet Mol Res 15, doi:10.4238/gmr.15038583 (2016). 87 Scott, L. C. et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101, 410-417, doi:10.1038/sj.bjc.6605175 (2009). 88 Lorente, L. et al. Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. Int J Mol Sci 17, doi:10.3390/ijms17091524 (2016). 89 Moll, R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31, 205-262 (1998). 90 Afrem, M. C. et al. Study of CK18 and GDF5 immunoexpression in oral squamous cell carcinoma and their prognostic value. Rom J Morphol Embryol 57, 167-172 (2016). 91 Yang, Z. Y. et al. [Expression of cytokeratin(CK)7, CK8/18, CK19 and p40 in esophageal squamous cell carcinoma and their correlation with prognosis]. Zhonghua Bing Li Xue Za Zhi 47, 834-839, doi:10.3760/cma.j.issn.0529-5807.2018.11.004 (2018). 92 Marceau, N., Loranger, A., Gilbert, S., Daigle, N. Champetier, S. Keratin-mediated resistance to stress and apoptosis in simple epithelial cells in relation to health and disease. Biochem Cell Biol 79, 543-555 (2001). 93 Inada, H. et al. Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol 155, 415-426, doi:10.1083/jcb.200103078 (2001). 94 Sullivan, B. T. et al. Cytokeratin 18 expression inhibits cytokine-induced death of cervical cancer cells. Int J Gynecol Cancer 20, 1474-1481, doi:10.1111/IGC.0b013e3181fc3a03 (2010). 95 Leifeld, L. et al. Keratin 18 provides resistance to Fas-mediated liver failure in mice. Eur J Clin Invest 39, 481-488, doi:10.1111/j.1365-2362.2009.02133.x (2009). 96 Yoon, H. N., Yoon, S. Y., Hong, J. H. Ku, N. O. A mutation in keratin 18 that causes caspase-digestion resistance protects homozygous transgenic mice from hepatic apoptosis and injury. J Cell Sci 130, 2541-2550, doi:10.1242/jcs.187492 (2017). 97 Bauman, P. A., Dalton, W. S., Anderson, J. M. Cress, A. E. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci U S A 91, 5311-5314, doi:10.1073/pnas.91.12.5311 (1994). 98 Chalabi, N. et al. Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. Cancer Genomics Proteomics 5, 253-261 (2008). 99 Schaller, G. et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 2, 1879-1885 (1996). 100 Schaller, G. et al. [The clinical importance of keratin 18 in breast cancer]. Zentralbl Gynakol 121, 126-130 (1999). 101 Schaafsma, H. E. et al. Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma. J Pathol 170, 77-86, doi:10.1002/path.1711700113 (1993). 102 Kabukcuoglu, S., Ozalp, S. S., Yalcin, O. T., Colak, E. Abubakar, A. A. Comparison of histopathologic classification and surgical stage by cytokeratin 8 and cytokeratin 18 in endometrial cancer. Eur J Gynaecol Oncol 31, 641-644 (2010). 103 Morisaki, T. et al. Comparative proteomics analysis of gastric cancer stem cells. PLoS One 9, e110736, doi:10.1371/journal.pone.0110736 (2014). 104 Lee, C. F. et al. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J Gastroenterol 15, 356-365, doi:10.3748/wjg.15.356 (2009). 105 Yamaguchi, H., Wyckoff, J. Condeelis, J. Cell migration in tumors. Curr Opin Cell Biol 17, 559-564, doi:10.1016/j.ceb.2005.08.002 (2005). 106 Chu, Y. W., Seftor, E. A., Romer, L. H. Hendrix, M. J. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol 148, 63-69 (1996). 107 Walsh, N. et al. Identification of pancreatic cancer invasion-related proteins by proteomic analysis. Proteome Sci 7, 3, doi:10.1186/1477-5956-7-3 (2009). 108 Fortier, A. M., Asselin, E. Cadrin, M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem 288, 11555-11571, doi:10.1074/jbc.M112.428920 (2013). 109 Buhler, H. Schaller, G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 3, 365-371, doi:10.1158/1541-7786.MCR-04-0117 (2005). | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78429 | - |
| dc.description.abstract | 目的 細胞角蛋白18 (K18)是上皮組織中常見的細胞骨架蛋白。K18的異常表現與多種癌症的進展有關，不過K18在口腔鱗狀細胞癌(OSCC)中的功能尚未被完全釐清。本研究將會探討K18的表現在OSCC組織中對病患臨床病理特徵和預後的影響。 方法 透過免疫組織化學染色(IHC)分析88位OSCC病患手術後切除的腫瘤中K18表現情形，並進一步分析K18表現與多種臨床病理特徵、預後的相關性。 結果 K18的表現與多顆淋巴結轉移有關，與腫瘤大小無關，K18高度表現與淋巴血管侵犯(LVI)有關。在存活分析中顯示K18陽性病患相較於K18陰性病患會有較短的整體存活期，而且K18強陽性病患還會有更短的無病存活期。 結論 在台灣OSCC病患中K18表現與較差的預後有關。K18高度表現與淋巴血管侵犯(LVI)有關。K18對於OSCC侵襲力增加有重要的作用，有可能是OSCC潛在的治療標靶。 | zh_TW |
| dc.description.abstract | Purpose Cytokeratin 18 (K18) is a cytoskeleton protein that is normally expressed in epithelium. Aberrant K18 expression is associated with cancer progression. However, the functions of K18 in oral cancer have not been fully elucidated. The present study aims to further investigate the association of K18 expression in clinicopathological parameters and prognosis of oral squamous cell carcinoma (OSCC) patients. Methods This study evaluated K18 expression by immunohistochemistry in 88 resected specimens from patients with OSCC. The relationship between K18 expression levels and various clinicopathological parameters and prognosis were further analyzed. Results K18 expression was significantly correlated to the number of pathologically positive lymph nodes but not to tumor size. Strongly positive of K18 was significantly correlated to lymphovascular invasion(LVI). Kaplan-Meier survival analysis showed that OSCC patients with positive K18 had a significantly poorer overall survival than negative K18 group. Furthermore, patients with high intensity of K18 had a significantly poorer disease-free survival than negative K18 group. Conclusions The expression of K18 was significantly associated with the poor prognosis of OSCC in Taiwan. Strongly positive of K18 expression was significantly correlated to lymphovascular invasion. K18 plays an invasion‐promoting role in OSCC and might be a potential therapeutic target in the treatment of OSCC. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:56:33Z (GMT). No. of bitstreams: 1 U0001-2701202101415200.pdf: 19316737 bytes, checksum: 6bb35ec211b22c755797296b84a0c1a6 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員會審定書 I 誌謝 II 中文摘要 III 英文摘要 IV 第一章 研究背景與動機 1 1.1 口腔癌在台灣的現況 1 1.2 口腔鱗狀細胞癌(OSCC)的存活率 1 1.3細胞角蛋白(Cytokeratin) 2 1.4 細胞角蛋白8/18與鱗狀細胞癌的關係 3 1.5 細胞角蛋白18與口腔鱗狀細胞癌的關係 4 1.6細胞角蛋白18對各種癌症的影響 6 第二章 假說及研究目的 7 2.1 假說 7 2.2 研究目的 7 第三章 實驗材料與研究方法 8 3.1病患與研究樣本 8 3.2臨床資料收集 8 3.3免疫組織化學染色(Immunohistochemistry) 9 3.4組織切片的觀察與拍照 10 3.5 IHC染色結果的判定 10 3.6統計分析 11 第四章 結果 13 4.1病例資料 13 4.2 K18在OSCC上的表現 14 4.3 K18的表現與臨床病理特徵的相關性 15 4.4 K18的表現對於預後的影響 18 第五章 討論 20 5.1本研究中K18表現與OSCC的關係 20 5.2 K18異常表現與腫瘤進展 21 5.3 K18表現與腫瘤分化程度 22 5.4 K18表現對放射線抗拒性和細胞凋亡的影響 23 5.5 K18表現對預後的影響 24 5.6 K18表現對淋巴結轉移和侵襲力的影響 25 5.7本研究的限制 29 5.8 K18在OSCC未來的發展與應用 30 第六章 結論 31 第七章 圖 32 第八章 表 49 參考文獻 64 | |
| dc.language.iso | zh-TW | |
| dc.subject | 細胞角蛋白18 | zh_TW |
| dc.subject | 免疫組織化學染色 | zh_TW |
| dc.subject | 口腔癌 | zh_TW |
| dc.subject | 口腔鱗狀細胞癌 | zh_TW |
| dc.subject | 淋巴血管侵犯 | zh_TW |
| dc.subject | 淋巴結轉移 | zh_TW |
| dc.subject | 預後 | zh_TW |
| dc.subject | Prognosis | en |
| dc.subject | Cytokeratin 18 | en |
| dc.subject | CK18 | en |
| dc.subject | KRT18 | en |
| dc.subject | K18 | en |
| dc.subject | Immunohistochemistry | en |
| dc.subject | IHC | en |
| dc.subject | Oral Squamous Cell Carcinoma | en |
| dc.subject | OSCC | en |
| dc.subject | Lymph Node Metastasis | en |
| dc.subject | Lymphovascular Invasion | en |
| dc.subject | LVI | en |
| dc.title | 在台灣口腔鱗狀細胞癌中細胞角蛋白18的表現與臨床病理特徵和預後的關係 | zh_TW |
| dc.title | Association of Cytokeratin 18 Expression with Clinicopathological Parameters and Prognosis of Oral Squamous Cell Carcinoma in Taiwan | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.author-orcid | 0000-0003-4543-2512 | |
| dc.contributor.coadvisor | 張玉芳(Yu-Fong Chang) | |
| dc.contributor.oralexamcommittee | 蔡丰喬(Feng-Chiao Tsai) | |
| dc.subject.keyword | 細胞角蛋白18,免疫組織化學染色,口腔癌,口腔鱗狀細胞癌,預後,淋巴結轉移,淋巴血管侵犯, | zh_TW |
| dc.subject.keyword | Cytokeratin 18,CK18,KRT18,K18,Immunohistochemistry,IHC,Oral Squamous Cell Carcinoma,OSCC,Prognosis,Lymph Node Metastasis,Lymphovascular Invasion,LVI, | en |
| dc.relation.page | 74 | |
| dc.identifier.doi | 10.6342/NTU202100199 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2021-01-28 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
| dc.date.embargo-lift | 2026-01-27 | - |
| 顯示於系所單位： | 口腔生物科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2701202101415200.pdf 未授權公開取用 | 18.86 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。